Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (ABT)
NYSE:ABT
Abbott Laboratories (ABT) Stock Price & Analysis
7,195 Followers
ABT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$88.80 - $121.04
Previous Close$104.01
Volume7.04M
Average Volume (3M)5.73M
Market Cap
$180.94B
Enterprise Value$189.11B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$14.59B
Price to Earnings (P/E)32.4
Beta0.69
Next Earnings
Jul 18, 2024EPS Estimate
$1.11Last Dividend Ex-Date
Apr 12, 2024Dividend Yield2.04%
Share Statistics
EPS (TTM)3.21
Shares Outstanding1,739,633,759
10 Day Avg. Volume5,174,662
30 Day Avg. Volume5,730,615
Standard Deviation0.06
R-Squared0.43
Alpha0.00018
Financial Highlights & Ratios
Price to Book (P/B)25.61
Price to Sales (P/S)18.29
Price to Cash Flow (P/CF)44.40
P/FCF Ratio61.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.69
Enterprise Value/Gross Profit8.54
Enterprise Value/Ebitda18.17
Forecast
1Y Price Target
$128.60Price Target Upside23.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Abbott Laboratories News
PremiumStock Analysis & Ideas
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
PremiumCompany Announcements
Abbott Labs EVP of Finance Robert Funck Retires After 36 YearsBulls Say, Bears Say
Bulls Say
Financial PerformanceABT's robust financial performance is evidenced by a strong top-line beat and an increase in projected organic sales growth, underpinned by consistent double-digit growth and a positive outlook for future revenue.
Market OpportunityABT's Esprit BTK system stands out in the market with its unique design, reducing common complications associated with other treatments and is now the only FDA-approved drug-eluting system for below-the-knee treatments in the US.
Regulatory ApprovalThe FDA has approved ABT's Esprit BTK, a pioneering treatment for chronic limb-threatening ischemia, marking a significant milestone in addressing a major health issue affecting over 200 million people globally.
Bears Say
Legal ChallengesThe company is named as a defendant in a significant number of federal and state NEC cases, which could potentially lead to substantial damages.
Market CompetitionCompetition in the US market has led to a slight decline in the company's device segment, reflecting the challenges it faces in maintaining market share.
Product Efficacy And Safety ConcernsSome panelists expressed concerns that TriClip procedure may limit future treatment options like defibrillators/pacemakers or afib ablation.
---
Ownership Overview
2.79% Insiders
26.26% Mutual Funds
39.71% Other Institutional Investors
31.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $88.80 and its highest was $121.04 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jul 18, 2024 which is in 64 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Apr 17, 2024. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.955 by $0.025.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 2.04%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.11.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,739,633,800 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $0.98 in its last earnings report, beating expectations of $0.955. Following the earnings report the stock price went down -3.031%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$128.60 (23.64% Upside)
$128.60 (23.64% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 164.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.95%
12-Months-Change
Fundamentals
Return on Equity
14.80%
Trailing 12-Months
Asset Growth
-1.80%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
ABT Company Deck
---
ABT Earnings Call
Q1 2024
0:00 / 0:00
---
ABT Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
ABT Stock 12 Month Forecast
Average Price Target
$128.60
▲(23.64% Upside)
Technical Analysis
Best Analysts Covering ABT
1 Year
1 Year Success Rate
39/47 ratings generated profit
1 Year Average Return
+18.63%
reiterated a buy rating 28 days ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 82.98% of your transactions generating a profit, with an average return of +18.63% per trade.
---